Physician profile
Kandi Weber
NPI 1235763079
$6,873.63
in general payments reported to CMS, 2019-2025
41 companies · $1,707 in 2025
The $1,707 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $857 · 2022: $1,282 · 2023: $1,575 · 2024: $1,452 · 2025: $1,707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,734.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,177.13 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $842.78 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $676.58 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $616.82 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $365.65 | 2023-2025 | |
| Lilly USA, LLC | $365.53 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $322.19 | 2021-2025 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $275.91 | 2022-2024 | Verquvo, Belsomra, Steglatro |
| Corcept Therapeutics | $238.98 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $193.17 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $175.75 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.63 | 2021-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.28 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $130.11 | 2022 | |
| Axsome Therapeutics, INC. | $122.19 | 2023-2025 | Auvelity |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $104.15 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $81.71 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.54 | 2022-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $70.20 | 2022-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $59.38 | 2022-2023 | Xarelto |
| Sumitomo Pharma America, INC. | $59.05 | 2023-2024 | Gemtesa |
| Amarin Pharma, INC. | $49.25 | 2022 | |
| Avanir Pharmaceuticals, INC. | $49.05 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $44.60 | 2023 | Rexulti |
| Lundbeck LLC | $44.51 | 2025 | Rexulti |
| Upsher-Smith Laboratories LLC | $42.31 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $39.22 | 2022-2024 | Zoryve, Livalo, Seglentis |
| Corium, LLC | $38.87 | 2022-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $38.57 | 2021-2023 | Qelbree |
| Vanda Pharmaceuticals INC. | $35.90 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $33.32 | 2024-2025 | Eliquis, Camzyos |
| Idorsia Pharmaceuticals US INC | $33.01 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $32.71 | 2024-2025 | Cologuard Collection Kit |
| Indivior INC. | $27.12 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.75 | 2021 | |
| Viatris Specialty LLC | $16.21 | 2025 | Yupelri |
| Orexo US, INC. | $15.57 | 2021 | |
| Mylan Specialty L.P. | $14.61 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.46 | 2021 | |
| Dexcom, INC. | $13.80 | 2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $13.06 | 2023 | Tlando, Xyosted, Nocdurna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kandi Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.